Core Insights - The collaboration between Hansoh Pharmaceutical and Roche highlights the increasing significance of Chinese biotechnology in the global innovation landscape [1] - The agreement allows Roche to develop, produce, and commercialize the ADC HS-20110 outside Greater China, with a total deal value potentially reaching $1.45 billion [1][2] Financial Terms - Hansoh Pharmaceutical will receive an upfront payment of $80 million, with additional milestone payments tied to the drug's development and commercialization progress [2] - The total potential value of the agreement, including milestone payments and tiered royalties from future sales, could reach $1.45 billion [2] Focus Asset - HS-20110 is a targeted ADC aimed at CDH17, currently in global Phase I clinical trials for treating colorectal cancer and other solid tumors, addressing a significant unmet medical need [3] - Roche's substantial investment indicates confidence in HS-20110's potential as an innovative therapy [3] Global Licensing and Market Division - The licensing agreement is a typical "license-out" collaboration, with Hansoh retaining rights in Greater China while Roche secures exclusive rights in all other global markets [4] - This partnership allows Hansoh to leverage Roche's extensive global clinical development and commercialization network while focusing on its domestic market [4]

Core Insights - The Hang Seng Index closed down 22 points, reflecting a volatile performance in the Hong Kong stock market, with significant fluctuations throughout the trading day [3][4] - The technology sector negatively impacted the market, with major companies like Xiaomi, Tencent, and Meituan experiencing declines [4] - The overall market saw a net inflow of capital from the north, amounting to 158.21 million [3] Market Performance - The Hang Seng Index opened lower at 25,890 points, peaked at 26,062 points, but ultimately closed at 25,888 points, down 0.09% [3] - Among 88 blue-chip stocks, 46 rose while 40 fell, indicating mixed performance across sectors [4] - The trading volume for the day was 27.54 billion [3] Technology Sector Developments - The Hong Kong Science Park Company announced the development of the INNOPOLE project, aimed at fostering innovation and economic growth in Hong Kong, with an initial phase covering approximately 2.5 hectares [7] - The Hong Kong Stock Exchange reported a significant increase in the number of hard technology companies applying for listings, with about 280 companies currently in the application process, half of which are technology firms [8] Smartphone Market Insights - In the third quarter, smartphone shipments in mainland China decreased by 2.75% year-on-year, with Vivo leading the market share at 18% despite a 9.23% decline in shipments [9] - The overall smartphone market has seen consecutive declines, but the rate of decline is narrowing, suggesting potential recovery in the upcoming quarter [9] Company-Specific News - Xtep International reported low single-digit growth in retail sales for the third quarter, with inventory turnover ranging from 4 to 4.5 months [11] - Hansoh Pharmaceutical entered a licensing agreement with Roche, receiving an upfront payment of $80 million (approximately 624 million HKD) and potential milestone payments totaling up to $1.45 billion (approximately 1,131 million HKD) [12] - China Tower reported a 6.81% year-on-year increase in profit for the first nine months, with total revenue growing by 2.58% [13] - China Pacific Insurance expects a net profit increase of approximately 40% to 60% for the first three quarters, driven by improved operational management and capital market performance [14]

每经AI快讯，翰森制药(03692.HK)高开近4%，截至发稿，涨3.92%，报37.14港元，成交额460.54万港 元。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd, granting Roche exclusive global rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The licensing agreement was established between Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. (collectively referred to as "licensors") and Roche (the "licensee") [1] - The licensors will receive an upfront payment of $80 million and are eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Additionally, the licensors will receive tiered royalties on future potential product sales [1] Group 2: Company Background - Roche is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange and was founded in 1896 in Basel, Switzerland [1] - Roche has evolved into a leading global biotechnology company and a leader in in vitro diagnostics [1] - The board of Hansoh Pharmaceutical believes that entering into this licensing agreement is in the best interests of the company and its shareholders [1]

Core Viewpoint - Hansoh Pharmaceutical announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate for colorectal cancer and other solid tumors [1] Group 1: Licensing Agreement Details - The agreement involves Hansoh's wholly-owned subsidiary Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. as licensors [1] - Hansoh will receive an upfront payment of $80 million and is eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Future potential sales will also generate tiered royalties for Hansoh [1] Group 2: Product and Clinical Trials - HS-20110 is currently undergoing global Phase I clinical trials in China and the United States for the treatment of colorectal cancer and other solid tumors [1] - The product represents a significant advancement in targeted cancer therapy, leveraging antibody-drug conjugate technology [1] Group 3: Roche Overview - F. Hoffmann-La Roche Ltd is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange [1] - Roche was established in 1896 in Basel, Switzerland, and has evolved into a leading global biotechnology company and a leader in in vitro diagnostics [1]

Core Viewpoint - Hansoh Pharmaceutical announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement involves Hansoh's wholly-owned subsidiary Shanghai Hansoh Biopharmaceutical Technology Co., Ltd. and Changzhou Hengbang Pharmaceutical Co., Ltd. as licensors [1] - Hansoh will receive an upfront payment of $80 million and is eligible for up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - The product, HS-20110, is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently undergoing global Phase I clinical trials for colorectal cancer (CRC) and other solid tumors in China and the United States [1] Group 2: Company and Market Context - The licensee, F. Hoffmann-La Roche Ltd, is a subsidiary of Roche Holding AG, which is listed on the Swiss Stock Exchange [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has entered into a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, a CDH17-targeted antibody-drug conjugate, excluding mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The agreement involves a payment of $80 million as an upfront fee to Hansoh Pharmaceutical [1] - Hansoh is eligible to receive up to $1.45 billion in milestone payments based on the product's development, regulatory approval, and commercialization progress [1] - Future potential sales will also generate tiered royalties for Hansoh [1] Group 2: Product and Clinical Trials - HS-20110 is currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in both China and the United States [1] Group 3: Company Background - Roche Holding AG, the parent company of the licensee, is a leading global biotechnology company and a pioneer in the pharmaceutical manufacturing industry, established in 1896 in Basel, Switzerland [1] - The board of Hansoh believes that this licensing agreement aligns with the best interests of the company and its shareholders, maximizing the scientific and commercial value of its technology platform [1]

Core Insights - Hansoh Pharmaceutical (03692) announced a licensing agreement with F. Hoffmann-La Roche Ltd for the global exclusive rights to develop, manufacture, and commercialize HS-20110, excluding mainland China, Hong Kong, Macau, and Taiwan [1][2] - The agreement includes an upfront payment of $80 million, with potential milestone payments of up to $1.45 billion based on the product's development, regulatory approval, and commercialization progress, along with tiered royalties on future sales [1] - HS-20110 is an investigational CDH17-targeted antibody-drug conjugate (ADC) currently undergoing global Phase I clinical trials for the treatment of colorectal cancer (CRC) and other solid tumors in China and the United States [1] Company Overview - Roche Holding AG, the parent company of the licensee, is a leading global biotechnology company and a leader in in vitro diagnostics, established in 1896 in Basel, Switzerland [2] - The board of Hansoh Pharmaceutical believes that entering into this licensing agreement aligns with the overall best interests of the company and its shareholders, maximizing the scientific and commercial value of its technology platform [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 內幕消息 與羅氏訂立許可協議 本公告乃由翰森製藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根 據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章證券及期貨條例第XIVA部的內幕消息條文（定義見上市規則）而作出。 根據許可協議，許可人將授予被許可人開發、生產及商業化HS-20110（「該產品」） 的全球獨佔許可（不含中國內地、香港、澳門和台灣）。許可人將獲得8,000萬美元 首付款，並有資格根據該產品開發、註冊審批和商業化進展收取最高14.5億美元 里程碑付款，以及未來潛在產品銷售的分級特許權使用費。 該產品是一款在研CDH17靶向抗體–藥物偶聯物(ADC)，目前正在中國和美國開 展用於治 ...

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 2.42% on October 16, with a trading volume of 1.486 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of October 15, 2024, the fund's shares reached 8.213 billion, with a total size of 7.102 billion yuan, reflecting a significant increase of 1977.25% in shares and 1779.88% in size compared to December 31, 2023 [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 68.94% since taking over the fund on January 3, 2024 [2] - The ETF's top holdings include companies such as Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant percentages of the portfolio allocated to these stocks [2] Trading Activity - Over the last 20 trading days, the ETF recorded a cumulative trading amount of 30.962 billion yuan, averaging 1.548 billion yuan per day [1] - Since the beginning of the year, the ETF has seen a total trading amount of 222.219 billion yuan over 189 trading days, averaging 1.176 billion yuan per day [1]